

Reply to Letter to the Editor: "Is a Single Nitroglycerin Study Sufficient to Say that It Is Safe Not to Give Nitroglycerin Before Radial Intervention?"

To the Editor,

We appreciate the interest shown by the authors¹ in our article titled "Impact of Nitroglycerin Injection on Radial Artery Outcomes in Distal Transradial Access" published in *Anatol J Cardiol* 2025; 29(3): 139144,² and we thank them for their thoughtful comments and valuable questions.

Regarding the first question concerning the troponin values presented in Table 1, we appreciate the opportunity to clarify this point. As noted, the study cohort included both elective and emergency cases, and the troponin values reflect the laboratory findings at the time of each patient's presentation. The upper reference limit for troponin in our institution is 4 ng/mL. Elevated troponin levels were predominantly observed in patients who underwent urgent or emergency procedures.

We agree that indicating the normal reference range in the table would have provided additional clarity. Addressing the second comment, we recognize the relevance of nitroglycerin not being administered uniformly across the study population. Since our study was retrospective, the decision to administer nitroglycerin was left to the discretion of the operator. Although the prophylactic use of intra-arterial nitroglycerin is supported, its use in practice can be influenced by various factors, including clinical judgment, patient-specific contraindications (increased intracranial pressure, severe anemia, right-sided myocardial infarction, or nitroglycerin hypersensitivity), or differing institutional protocols.^{3,4} Regarding the third question, although we collected lipid profile data for a subset of patients, no statistical analysis was performed to assess their impact on the study outcomes, as our study was specifically designed to investigate the effect of nitroglycerin administration on radial artery outcomes. Moreover, radial artery diameter was not systematically measured in our center at the time of the study. We recognize the clinical importance of these parameters and suggest that future prospective studies should explore their impact.

Declaration of Interests: The authors have no conflicts of interest to declare.

Funding: The authors declare that this study received no financial support.

REFERENCES

1. Ömür SE, Zorlu Ç. Is a single nitroglycerin study sufficient to say that it is safe not to give nitroglycerin before radial intervention? *Anatol J Cardiol*. 2025;29(11):669.
2. Karaca M, Dağdeviren B. Impact of nitroglycerine injection on radial artery outcomes in distal transradial access. *Anatol J Cardiol*. 2025;29(3):139-144. [CrossRef]
3. Ishikura F, Beppu S, Hamada T, Khandheria BK, Seward JB, Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. *Circulation*. 2000;102(20):2516-2521. [CrossRef]
4. Twiner MJ, Hennessy J, Wein R, Levy PD. Nitroglycerin use in the emergency department: current perspectives. *Open Access Emerg Med*. 2022;14:327-333. [CrossRef]



Copyright@Author(s) - Available online at anatoljcardiol.com.
Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

LETTER TO THE EDITOR REPLY

Mehmet Karaca

Bahadır Dağdeviren

Department of Cardiology, Private
Ataşehir Memorial Hospital, Istanbul,
Türkiye

Corresponding author:

Mehmet Karaca
✉ mehmetkaraca06@gmail.com

Cite this article as: Karaca M,
Dağdeviren B. Reply to letter to the
editor: "Is a single nitroglycerin study
sufficient to say that it is safe not to
give nitroglycerin before radial
intervention?" *Anatol J Cardiol*.
2025;29(11):670.

DOI:10.14744/AnatolJCardiol.2025.5529